News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Conference News AHA 2022 ‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge L.A. McKeown November 11, 2022
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ACC 2022 POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery Todd Neale April 02, 2022
News Conference News AXIOMATIC-TKR: Milvexian Promising for VTE Prevention L.A. McKeown November 15, 2021
News Conference News HRS 2021 STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation Todd Neale July 29, 2021
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Conference News ESC 2020 Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism Caitlin E. Cox September 04, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017